Home > Riviste > Giornale Italiano di Dermatologia e Venereologia > Fascicoli precedenti > Giornale Italiano di Dermatologia e Venereologia 2018 June;153(3) > Giornale Italiano di Dermatologia e Venereologia 2018 June;153(3):403-18

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Permessi
Per citare questo articolo

 

REVIEW   Freefree

Giornale Italiano di Dermatologia e Venereologia 2018 June;153(3):403-18

DOI: 10.23736/S0392-0488.18.05936-9

Copyright © 2018 EDIZIONI MINERVA MEDICA

lingua: Inglese

Cutaneous squamous cell carcinoma and the emerging role of sentinel lymph node biopsy

Cristian NAVARRETE-DECHENT 1, 2, Michael J. VENESS 3, 4, Nicolas DROPPELMANN 2, 5, Pablo URIBE 1, 2

1 Department of Dermatology, Faculty of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile; 2 Melanoma and Skin Cancer Unit, Faculty of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile; 3 Department of Radiation Oncology, Westmead Hospital, Westmead, Sydney, Australia; 4 Faculty of Medicine, Sydney University, Sydney, Australia; 5 Surgical Oncology, Faculty of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile


PDF


Cutaneous squamous cell carcinoma (cSCC) is the second most common skin cancer and is usually associated with a favorable prognosis in most patients. However, a small minority of patients will be diagnosed with a high-risk cSCC (HRcSCC) and a proportion will have a poor outcome, in some cases causing death. HRcSCC is characterized by an increase in aggressiveness manifested as local recurrence, the development of lymph node metastases, and occasionally death. The utility of sentinel lymph node biopsy (SLNB) in this group of patients is unclear without high-level evidence or clear-cut recommendations. If clinicians accept as a cut-off threshold of a >10% of risk of harboring occult nodal metastasis, then selected HRcSCC patients may benefit from SLNB and/or additional investigations. Herein, we performed a review of the current evidence regarding SLNB in HRcSCC. We believe that SLNB may be considered in selected HRcSCC patients to potentially better predict prognosis and influence management. However larger prospective studies are needed to better define the subset of patients that may benefit from SLNB and if early detection of occult nodal metastases is associated with an improved outcome.


KEY WORDS: Carcinoma, squamous cell - Sentinel lymph node biopsy - Lymph nodes - Neoplasm metastasis - Skin neoplasms

inizio pagina